Response of Human Red Blood Cells to Acute and Chronic Oxidant Challenge as Observed Through the Glutathione and Glutathionyl-Hemoglobin Redox Pairs In Vitro and In Vivo

TL;DR

This study examines how human red blood cells respond to oxidative stress by analyzing glutathione and glutathionyl-hemoglobin redox pairs in both lab and real-world conditions.

Contribution

The paper introduces a new electrochemical framework to better understand redox processes in erythrocytes under oxidative stress.

Findings

HbSSG accumulation in chronic oxidative stress is linked to impaired enzyme activity, not GSH availability.

Smokers show consistent HbSSG levels, but GSSG/GSH redox potentials vary widely.

Dehydro-alanine analogs of GSH from butadiene and busulfan may impair redox enzyme function.

Abstract

Glutathionyl-hemoglobin (HbSSG) reversibly forms under oxidative stress in erythrocytes, where it constitutes the main redox buffer, in a dynamic equilibrium with the thiol (GSH) and disulfide (GSSG) forms of glutathione, that quickly revert to the reduced thiols when oxidative pressure is relieved. Under acute challenge, the “oxidized” GSH pool distributes between GSSG and HbSSG. Recalculation with electrochemical metrics based on redox potentials of the GSSG/GSH and HbSSG/HbSH pairs, plotted in their phase space, improves the understanding of the competing reduction processes. The first process is reduction of the GSSG pool, while, later, HbSSG reduction occurs as a two-step process. HbSSG accumulation in chronic oxidative stress follows an impairment of these steps. In 30 strong smokers, homogeneous levels of HbSSG are in the range of 2.4–11.7% (Eh −120–−95 mV), but the Eh of the GSSG/GSH redox pair is wider (−160–−240 mV), suggesting that HbSSG accumulation does not depend on GSH availability but on enzyme activity impaired by exogenous and endogenous electrophiles. As hinted by HbSSG measurements, one such species is the dehydro-alanine analog of GSH, produced both from butadiene in exposed petrochemical workers and from the drug busulfan in a treated patient. Inactivation of the low-copy recycling enzymes can thus explain the increase of HbSSG.

Figures